Drug intelligence / Profile preview

HC-SVT-1002

Development stage: Unknown
Lead developer: Laboratorios Salvat
Modality: Stem Cell Therapies → Cell Therapies
Administration: Implant

Overview

HC-SVT-1002 is an allogeneic cell therapy product developed by Salvat for the treatment of atrophic pseudarthrosis (nonunion) of long bones. It consists of expanded allogeneic adipose-derived mesenchymal stem cells (AD-MSCs) combined with a tricalcium phosphate (TCP) biomaterial scaffold. The AD-MSCs provide osteogenic potential and secrete trophic factors to promote bone healing, while the TCP serves as an osteoconductive scaffold. This combination is designed to be applied surgically to the site of the nonunion to stimulate bone regeneration in cases where natural healing has failed.

Other names: Allogeneic Fat Stem Adult Mesenchymal Cells Expanded and Combined With a Tricalcium Phosphate Biomaterial

Beyond the preview

Go deeper on HC-SVT-1002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HC-SVT-1002.

Explore the full profile